Company Data

ZyVersa Therapeutics Inc

Fundamental Analysis:
ZyVersa Therapeutics Inc
ZyVersa Therapeutics Inc
Fundamental Analysis:
Current Price
$0.626 7.47%
Market Cap
Price Target
Refer to Report
52wk Range
$0.5 - $90.65
Advanced Market Data


ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with renal or inflammatory diseases who have significant unmet medical needs. Our development pipeline includes phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis (FSGS). VAR 200 has potential to treat other kidney diseases, such as Alport Syndrome and Diabetic Kidney Disease. It also includes a novel inflammasome ASC inhibitor with potential to treat multiple CNS and other inflammatory diseases.

Inbox Intel from Channelchek.

Informed investors make more money. And itโ€™s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
ยฉ 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.